Analyst: This Healthcare Stock Could Sink 43%

CRISPR Therapeutics is collaborating with Germany's ProBioGen

Jan 22, 2019 at 12:00 PM
facebook X logo linkedin

The shares of CRISPR Therapeutics AG (NASDAQ:CRSP) are getting hammered today, after the company entered an agreement with Germany's ProBioGen to research and develop gene-editing technology. Meanwhile, Citigroup poured salt in the proverbial CRSP wounds, downgrading the stock to "sell" from "neutral," and cutting its price target by $7 to $21 -- representing a 43% discount to the equity's close of $37.13 on Friday. At last check, the shares were down 13% to trade at $32.31, and put options are more active than usual.

CRSP stock is now set to snap a four-day winning streak, and is pacing for its worst day since Dec. 21, when the equity touched an annual low of $22.22. The stock has been in a channel of lower highs and lows since peaking at $73.90 in late May, giving up more than half its value in that time frame, with rebound attempts capped by its 100-day moving average.

CRSP stock chart jan 22

Already today, about 530 CRISPR Therapeutics put options have changed hands -- twice the average intraday pace. It appears bears are buying to open the February 32 put, which will become more profitable the further the stock slides beneath the $32 level by the close on Friday, Feb. 15, when the newly front-month options expire.

Today's appetite for puts runs counter to the recent trend, however. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 10-day call/put volume ratio stands at 3.79, indicating traders have bought to open nearly four CRSP calls for every put in the past two weeks. What's more, this ratio is in the 83rd percentile of its annual range, pointing to a healthier-than-usual appetite for bullish bets over bearish of late.

The security could be at risk of more negative analyst attention, too. Currently, seven of the 11 brokerage firms following CRSP maintain "buy" or better endorsements, with just one "sell" or worse on the books. Plus, the consensus 12-month price target of $63.72 is nearly double the equity's current price, leaving the door open for additional price-target cuts on the horizon.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI